HEALTHVIRGINIA MERCURY
Virginia budget expands Medicaid access to sickle cell gene therapy
Virginia lawmakers allocated $15 million over two years to expand Medicaid coverage for gene therapy treatments for sickle cell disease. The funding enables Virginia to separately pay for gene therapy drugs and associated care, improving access for Medicaid patients. Sentara-EVMS Comprehensive Sickle Cell Program serves over 200 adults in Hampton Roads, referring eligible patients to VCU Health for gene therapy, which involves a complex, months-long process including chemotherapy and cell infusion.
Mentioned
Related Signal
Adjacent reporting
- Virginia budget expands Medicaid access to sickle cell gene therapy
- Gene therapy for children with sickle cell disease approved by FDA
- FDA approves gene therapy for children with sickle cell disease ages 2+
- Aflac general counsel: Georgia lawmakers took a crucial step forward on sickle cell disease – but there’s more work to be done
- Opinion: $2 million gene therapy cures require a financing model